Growth Differentiation Factor-15 (GDF-15) is a Biological Marker in Heart Failure

The Russian Archives of Internal Medicine, Journal Year: 2023, Volume and Issue: 13(1), P. 14 - 23

Published: Jan. 25, 2023

Heart failure is an important medical, social and economic problem around the world. In recent years, a number of diagnostic prognostic biological markers blood in cardiovascular diseases have been studied. Identification new markers, analysis their pathophysiological aspects changes concentration under influence various treatment options, allow us to understand many pathogenetic features development course heart failure. decades, natriuretic peptides introduced into clinical practice, which are widely used as reliable for assessment. Growth differentiation factor-15 cytokine belonging family transforming growth factors, activity significantly increased stress inflammation. patients with chronic failure, this marker associated risk overall mortality adverse events; preserved left ventricular ejection fraction, use showed significance. Data from Framingham Study that was only multivariate statistically significant association all events. Eight studies overexpression It shown acute not inferior brain peptide precursor. To confirm value it necessary conduct extensive prospective randomized trials.

Language: Английский

---

Chronic heart failure: evolution of etiology, prevalence and mortality over the past 20 years

Terapevticheskii arkhiv, Journal Year: 2022, Volume and Issue: 94(1), P. 5 - 8

Published: Jan. 15, 2022

The article is devoted to the analysis of changes in role causal and comorbid risk factors for two main types heart failure with reduced preserved ejection fraction over previous 20 years. Within same time interval, dynamics prevalence mortality these clinical variants. Special attention paid a possible solution issue complexity recording cases diagnosis treatment chronic outpatient hospital practice.

Language: Английский

---

Features of diagnostics and treatment of chronic heart failure in elderly and senile patients. Expert opinion of the Society of Experts in Heart Failure, Russian Association of Gerontologists, and Euroasian Association of Therapists

Kardiologiia, Journal Year: 2018, Volume and Issue: 58(12S), P. 42 - 72

Published: Dec. 26, 2018

.

---

The risks of re-hospitalization of patients with heart failure with prolonged follow-up in a specialized center for the treatment of heart failure and in real clinical practice.

Kardiologiia, Journal Year: 2020, Volume and Issue: 60(3), P. 59 - 69

Published: May 3, 2020

Relevance The number of patients with functional class III-IV chronic heart failure (CHF) characterized by frequent rehospitalization for acute decompensated HF (ADHF) has increased. Rehospitalizations significantly increase the cost patient management and burden on health care system.Objective To determine effect long-term follow-up at a specialized center treatment (Center Treatment Chronic Heart Failure, CTCHF) risk after ADHF.Materials Methods study successively included 942 CHF ADHF. Group 1 consisted 510 who continued outpatient follows-up CTCHF, group 2 432 refused CTCHF were managed clinics their place residence. compliance recommendations frequency ADHF determined medical records structured telephone calls. A was recorded if stayed more than one day in hospital required intravenous loop diuretics. period two years. Statistical analyses performed using Statistica 7.0 software Windows, SPSS, R statistical package.Results Patients older, frequently had FC III less I 1. Both groups contained women preserved ejection fraction. Using method binary multifactorial logit-regression mathematical model created, which showed that during entire did not depend age sex but increased 2.4 times 3.4 2. Multinomial one, two, three or rehospitalizations within years higher (2.9-4.5 depending rehospitalizations) compared to I-II (2-3.2 rehospitalizations). Proportion readmitted first year greater (55.3 % vs. 39.8 [odd ratio (OR) =1.9; 95% confidence interval (CI), 1.4-2.4; р<0.001]; second year, proportion 67.4 28.2 (OR=5.3; 95 CI, 3.9-7.1; р<0.001). (р<0,001) whereas (р<0.001). Total (78.0 50.6 %) (OR=3.5; 2.6-4.6; Reasons identified 88.7 45.9 total 2, respectively. main cause non-compliance 47.4 66.7 respectively (р<0.001).Conclusion Follow-up system decreases both CHF. Despite education patients, personal contacts personnel, support, reasons avoidable.

Language: Английский

---

Characteristics and treatment of patients with heart failure admitted to a cardiology department in 2002 and 2016

Kardiologiia, Journal Year: 2018, Volume and Issue: 58(12S), P. 18 - 26

Published: Dec. 26, 2018

To investigate the difference in characteristics of patients admitted to Tomsk National Research Medical Center with a diagnosis heart failure (HF) 2002 and 2016.Medical charts all hospitalised single centre, HF, were included. Two three‑month periods compared from January (n=210) 2016 (n=378).Fewer HF had symptoms or required diuretics (63 % vs 98,6 %, p<0.001). During this period percentage HFpEF increased 58.6 74.1 (p=0.001) whereas those HFrEF remained similar (19.5 14.0 p=0.1) HFmrEF declined (21.9 11,9 p=0.007). In prescription ACEi / ARB (80.4 88 p=0.3), beta‑blockers 68 85 (p=0.03) aldosterone antagonists 9.7 49 (p<0.001).Prescription rates for prognostic medications improved 2016. The substantial diagnosed without diuretic raises question whether was appropriate some cases.

Language: Английский

---

City Center for the Treatment of Chronic Heart Failure: the organiza-tion of work and the effectiveness of treatment of patients with chronic heart failure

Kardiologiia, Journal Year: 2019, Volume and Issue: 59(2S), P. 31 - 39

Published: March 8, 2019

Actuality. In the Russian Federation, there has been an increase in number of patients with chronic heart failure (CHF) III–IV functional class, who are characterized by frequent development acute decompensation СHF and repeated hospitalizations. This dictates need to create a system effective control over conduct drug therapy physical rehabilitation after discharge from hospital at outpatient stage. Objective: identify differences between two strategies for monitoringatients CHF determine effectiveness treatment, measures life prognosis depending on observation specialized City Center Treatment (Heart clinic) real practice. Materials methods: The study included 648 hospitalized inpatient unit CHF. Group 1 consisted 412 who, discharge, continued follow-up department 2–326 preferred another departments Nizhny Novgorod. Results: After year observation, overall mortality rate group 2 was 14.83 %, 1–4.13 (odds ratio (OR) = 4.0, 95 % confidence interval (CI) 2.2–7.4; p <0.001). Cardiovascular also higher 2: 11.4 versus 3.3 (OR 3.8, CI 2.0–7.4; <0.001), as well decompensation: 7.6 2.1 1.7–8.7; 2, non-fatal cardiovascular complications were more common: 5.1 1.6 3.2, 1.2–8.3; 0.01), fatal nonfatal stroke, pulmonary thromboembolism, venous thromboembolic – 6.3 1.4 4.4, 1, 7–11.6; An proportion rehospitalized during compared recorded: 50.3 31.8 patients, respectively 2.2, 1.5–3.2; p<0.001). Physical activity observed significantly than among treated departments. Conclusion: Management Heart clinic showed better results comparison standard approach: risks general, statistically lower. Patients refused be seen often again year.

Language: Английский

---

Risk stratification of sudden cardiac death in heart failure patients: is left ventricular ejection fraction alone sufficient?

Russian Journal of Cardiology, Journal Year: 2021, Volume and Issue: 26(1), P. 3959 - 3959

Published: Feb. 17, 2021

According to current clinical guidelines, the risk of sudden cardiac death (SCD) in patients with heart failure is specified by left ventricular (LV) ejection fraction (EF). We believe that stratification and choice patient management tactics should be based on modern diagnostic techniques aimed at identifying anatomical electrophysiological substrate SCD. Therefore, LVEF alone not enough solve such problems. This review presents an analysis research novel predictors The most promising areas include identification electrocardiological markers fatal arrhythmias, ultrasound magnetic resonance imaging techniques. importance tests verification SCD discussed. Based literature analysis, we can conclude only a combination different factors significantly increase value prognostic model improve primary prevention

Language: Английский

---

Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction

Russian Journal of Cardiology, Journal Year: 2023, Volume and Issue: 28(3), P. 5386 - 5386

Published: April 14, 2023

Aim . To evaluate the cost-effectiveness of achieving target indicator "Reduction cardiovascular mortality population" State Program "Health Development" when using drugs valsartan+sacubitril, dapagliflozin and empagliflozin in patients with New York Heart Association (NYHA) class II-IV heart failure reduced ejection fraction ≤40% s 2023-2024. Material methods The population was Russian who received preferential medicines last two years after an acute disease. size determined on basis literary statistical sources. predict death, a parametric modeling method used based published data from clinical trials. amount drug costs required to prevent one as well achieve for reducing mortality, calculated each comparator whole country separately region. Results cost 1 st year therapy death case valsartan+sacubitril RUB 3,99 million, — 2,63 4,43 million. There were following empagliflozin: 2023 2197,9 1451,5 million 2435,9 respectively; 2024 627,4 407,7 706,9 respectively. Conclusion Among agents considered, seems be most effective preventing mortality"

Language: Английский

---

Relationships and Activities. The study is supported by OOO AstraZeneca Phar­maceuticals.

Russian Journal of Cardiology, Journal Year: 2023, Volume and Issue: 28(6), P. 5456 - 5456

Published: July 11, 2023

Heart failure (HF) is a global health problem. Despite advances in the development of effective treatments for patients with heart failure, morbidity and mortality from remain high, prognosis poor. However, there potential to improve outcomes HF current disease-modifying therapy. Planning needs resources, assessing effectiveness care clinical practice requires high-quality epidemiological data. Previously performed Russian observational studies were characterized by relatively small sample sizes, inclusion only one or few regions, strict selection criteria, single-stage design, short follow-up. The rationale design all-Russian prospective multicenter registry study "PRIORITET-CHF", which included 20000 throughout Federation, presented. main aims are (1) describe baseline demographic characteristics outpatients Federation (2) characterize routine therapy evaluate compliance treatment reduced ejection fraction guidelines.

Language: Английский

---

Assessment of prevalence and monitoring of outcomes in patients with heart failure in Russia

Russian Journal of Cardiology, Journal Year: 2020, Volume and Issue: 25(12), P. 4204 - 4204

Published: Dec. 30, 2020

The increasing prevalence of heart failure (HF) serves as a reverse side the effective treatment for cardiovascular diseases (CVD) and patient survival. Data on epidemiology HF related mortality in Russia are limited. According to EPOCHA trial (hospital phase), Russian Federation is 7%. can significantly contribute mortality. However, its recognition limited by peculiarities coding system Russia. article presents authors' view registration HF-related morbidity cases perspectives using left ventricular ejection fraction <50% statistical reporting.

Language: Английский

---